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Synopsis 
The role of palliative resection of the primary tumour in small intestinal (SI-NET) and 
pancreatic neuroendocrine tumours (P-NET) was evaluated through systematic review and 
meta-analysis. Overall survival was significantly longer in patients undergoing palliative 
resection of both P-NETs (HR 0.43; 95% CI: 0.34 - 0.57, p<0.001) and SI-NETs (HR 0.47; 95% 
CI: 0.35 - 0.55, p=0.007). 
 
Abstract 
Purpose: This study aimed to evaluate the impact on overall survival following palliative 
surgery to remove the primary lesion in unresectable metastatic small intestinal (SI-NET) and 
pancreatic neuroendocrine tumours (P-NET). 
Methods: A systematic review of the literature and meta-analysis was performed. MEDLINE 
and Embase databases were searched to identify articles comparing patients undergoing 
palliative primary tumour resection without metastatectomy vs. no resection. Relevant 
articles were identified in accordance with PRISMA guidelines. The primary outcome was 
overall survival. Included studies were evaluated for heterogeneity and publication bias. 
Results: 13 studies met the inclusion criteria, of which 6 presented data suitable for meta-
analysis. No randomised controlled trials were identified. Analysis of pooled multivariate 
hazard ratios demonstrated significantly longer overall survival in patients undergoing 
resection of both P-NETs (HR 0.43; 95% CI: 0.34 - 0.57, p<0.001) and SI-NETs (HR 0.47; 95% 
CI: 0.35 - 0.55, p=0.007). The increase in median survival in patients treated surgically 
relative to non-surgically ranged from 14 to 46 months in P-NET, and 22 to 112 months in SI-
NET. The number needed to treat in order that one additional patient was alive at five years, 
ranged from 3.0 to 4.2, and 1.7 to 7.7 respectively. 
Conclusions: Meta-analysis demonstrates that palliative resection of primary SI-NETs and P-
NETs in the setting of unresectable metastatic disease can increase survival. Although these 
results should be interpreted with caution due to potential selection and publication bias, 
the data supports consideration of surgery, particularly in patients with low tumour burdens 
and good functional status. 
 
 
Running Head: Palliative surgery in enteropancreatic NET 
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Introduction 
 
Enteropancreatic neuroendocrine tumours (EP-NETs) are a heterogeneous group of 
neoplasms with varying malignant potential and clinical manifestations. They arise from cells 
of the diffuse endocrine system of the intestinal tract and pancreas and frequently develop 
in the jejunum, ileum, appendix, and less commonly the hindgut, pancreas and duodenum.
1,2
 
The incidence of EP-NET has more than doubled in the past 15 years and they now represent 
the second most prevalent tumours of both  
the pancreas and the intestinal tract, occurring in 3.7 per 100,000 individuals per year.
3
 The 
majority of EP-NETs present with metastatic disease and their prognosis correlates closely 
with histological differentiation and grade as determined by mitotic rate and Ki67 index.
4
 
 
Approximately 70% of small intestinal NETs (SI-NET) are non-functioning, with the remainder 
presenting with, or developing, secretory features usually due to metastatic involvement of 
the liver, leading to carcinoid syndrome. Carcinoid syndrome can also occur through 
involvement of the ovaries and retro-peritoneal lymph nodes. A higher-proportion (close to 
50%) of pancreatic NETs (P-NET) are functioning lesions with very varied clinical 
manifestations, dependent on their hormonal activity. Functioning tumours, whether 
pancreatic or intestinal, are more common when associated with familial syndromes 
including MEN-1, vHL, and NF. 
 
Surgery with curative intent is indicated for EP-NET with liver metastases, provided there is 
absence of extra-hepatic metastases, diffuse bilobar liver involvement, or compromised 
hepatic function.
5
 Resection of the intestinal or pancreatic primary, in conjunction with 
synchronous or delayed liver resection can achieve cure, particularly in low-grade tumours.
6-
9,9,10,10,11
 However, the majority of EP-NETs present with unresectable stage IV disease, and 
the benefit of surgery to the primary lesion, particularly in asymptomatic non-secretory 
tumours, remains controversial. 
 
Palliative resection of the primary lesion is recommended for functioning tumours causing 
intractable secretory symptoms, as well as SI-NETs with impending intestinal obstruction or 
persistent bleeding. European Neuroendocrine Tumour Society (ENETS) 2016 guidelines also 
now recognise a potential survival benefit from primary tumour resection in incurable SI-
NETs and recommend consideration of palliative resection after careful assessment of 
patient comorbidities and functional status.
12
 Palliative resection of non-functioning P-NETs 
requires potentially morbid surgery and is not widely recommended, despite emerging data 
demonstrating a similar survival benefit in this cohort.
5,9,13,13-20
 
 
This systematic review and meta-analysis aimed to evaluate the impact on overall survival 
following resection of the primary tumour in patients with stage IV SI-NET and P-NET, as 
compared to non-operative treatments. 
 
 
Methods 
 
Data search 
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A systematic review of English language articles reporting outcomes of surgery in advanced 
SI-NET and P-NET was conducted in accordance with Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE (January 1946 to July 
2016) and Embase (January 1988 to July 2016) searches were conducted using the search 
terms “neuroendocrine tumour”, "EP-NET", “GEP-NET”, "pancreatic NET", "intestinal NET", 
"midgut NET", “carcinoid tumour”, "surgery", "resection", "primary", “metastases”, and/or 
“cytoreduction”. 
 
The titles and abstracts of all potentially relevant studies were reviewed for eligibility. The 
references of each of the included studies were also screened for any additionally relevant 
articles. 
 
Selection criteria 
 
All studies that reported survival in patients undergoing surgery in advanced unresectable SI-
NET and P-NET were evaluated. Studies that reported survival outcomes following a direct 
comparison between patients who underwent resection of their pancreatic or intestinal 
primary, versus those who did not undergo surgery, were included. Studies were excluded 
where surgery was undertaken with curative intent - both locally advanced disease where 
multivisceral resection or vascular reconstruction was necessary, and distant disease where 
metastatectomy or liver transplantation was performed. 
 
There were no exclusions based on tumour grade, patient numbers, length of follow-up, or 
patients' functional status. In both the operative and non-operative groups, other therapies 
(including SSA, chemotherapy, PRRT, TACE, and RFA) were permitted. 
 
In the case of duplicate or serial publications, the most recent or most complete data was 
included, and the other articles excluded from the analysis. In addition, abstracts that had 
not been published in full were excluded. 
 
Data extraction  
 
For each included study, the publication year, study design, type of surgery, site of primary 
tumour, number of included patients, median follow up and the age and gender 
distributions of patients were recorded, where available. Survival outcomes were extracted 
as hazard ratios (HRs) from univariable or multivariable Cox regression models, or as median 
survival times or survival rates at specific time points, as applicable.  Quality of life and 
symptomatic outcomes were not recorded, due to a sparsity of data. 
 
Statistical Methods 
 
Studies that reported adjusted hazard ratios for survival in the surgical versus non-surgical 
groups were pooled using a Mantel-Haenszel fixed effects meta-analysis model. Subgroup 
analyses were then performed within the SI-NET and P-NET studies, with comparisons made 
between these two groups. Heterogeneity was assessed using I
2
 statistics, and publication 
bias was reviewed graphically, using a funnel plot. 
 
In addition, a plot was produced which included all available survival data of any form from 
the included studies. Where median survival or the five year survival rates were reported, 
ratios were calculated for the surgical versus non-surgical groups. The resulting values were 
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plotted alongside the reported hazard ratios, against the sample size, in order to visualise 
the results of all studies regardless of the type of outcome reported. 
 
All meta-analyses were performed using the “metan” command in Stata 14 (StataCorp, 
2015), with p<0.05 classified as statistically significant throughout. 
 
 
Results 
 
Identification of Studies 
 
A total of 1257 studies were identified by the initial searches, of which 13 satisfied the 
inclusion criteria (Figure. 1). These studies included 2619 patients who underwent palliative 
surgical resection of their primary tumour (1395 P-NET; 1064 SI-NET.) One study was a 
prospective cohort series (Bettini), with the remainder being retrospective studies, based on 
either single-centre (N=9), multi-centre (N=1) or national database (N=2) cohorts. No 
randomised controlled trials were identified. 
 
Systematic Review and Meta-Analysis of Data 
 
Table 1 illustrates descriptive characteristics of the included studies. The number of included 
patients ranged from 42 to 614, and the average age from 49 to 63 years. Where the gender 
distributions were reported, most studies had similar numbers of males and females (% male 
ranging from 45%-57%). 
 
Of the thirteen papers that quoted survival outcomes for the surgical and non-surgical 
groups, six quoted an adjusted hazard ratio from a multivariable cox regression model (Table 
2). Three studies (Huttner
19
, Du
14
 and van der Hort-Schrivers
23
) additionally quoted hazard 
ratios from univariable analysis, which were consistent with the multivariable results (HR: 
0.47 vs. 0.41, 0.39 vs. 0.34 and 0.58 vs. 0.61 respectively). Hence, the meta-analysis was 
based on the multivariable results in order to maximise the number of studies available for 
analysis. 
 
The six studies included in the formal meta-analysis controlled for a range of different 
factors in their multivariable analyses (Table 1), with patient age the only factor to be 
considered in all studies. Franko et. al. only considered patient age and resection of the 
metastatic site in their multivariable analysis. They found the likelihood of resection to be 
highly dependent on tumour grade (79% of grade I/II vs. 25% of grade III/IV tumours were 
resected, p<0.001), but this factor could not be included in the analysis due to issues with 
multicollinearity.
22
 
 
Of the other studies included in the meta-analysis, just one controlled for other medical 
therapy
21
, and two made no attempt to control for markers of disease burden.
19,22
 In 
addition, no studies controlled directly for patient comorbidity in their multivariate analysis. 
 
Ahmed et. al. reported the results of the Cox regression model as relative risks, which were 
assumed to be incorrectly labelled hazard ratios. Givi et. al.
33
 included 8 patients that did not 
have SI-NET but had foregut / hindgut primaries, and Van der Horst-Schrivers et. al.
23
 
included 22 patients with an unknown primary site and 7 with a colonic primary. 
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The six studies included in the meta-analysis were combined using a fixed effects model, 
which found survival to be significantly improved in patients receiving surgery (p<0.001), 
with a pooled hazard ratio of 0.44 (95% CI: 0.35 – 0.55). Subgroup analysis found the benefit 
of surgery to be similar in the pancreas and small intestinal groups (p=0.793), with pooled 
hazard ratios of 0.43 (95% CI: 0.34 – 0.57, p<0.001) and 0.47 (95% CI: 0.27 – 0.81, p=0.007) 
respectively. Figure 2 displays a forest plot of the studies reporting adjusted hazard ratios. 
No significant heterogeneity was detected across the studies (I2=0%, p=0.578). A funnel plot 
was also produced (Figure 3), which gave no indication of publication bias. 
 
Seven studies did not report a hazard ratio and so were not included in the meta-analysis 
model. These studies quoted five year survival and/or median survival as their primary 
outcome (Table 2). Figure 4 incorporates these studies with those included in the meta-
analysis, and displays all reported outcomes. Across all 13 studies, patients undergoing 
primary tumour resection consistently had better survival outcomes than those that did not 
receive surgery. The single exception was the study by Bettini et. al. which reported a non-
significant reduction in five year survival after surgery  (40% surgical group 42% non-surgical 
group vs.; p=0.74), although the median survival was longer in the surgical group (54 vs. 40 
months). 
 
The reported increases in median survival in patients treated surgically relative to non-
surgically ranged from 14 - 46 months in P-NET (Solorzano et al, Franko et al.), and 22 - 112 
months (Strosberg et al., Givi et al.) in SI-NET. Based on the reported five year survival data, 
the number needed to treat (NNT) with palliative surgery, in order that one additional 
patient be alive at five years, ranged from 1.7 to 7.7 (Givi et al., van der Horst-Schrivers et 
al.) in the SI-NET cohort. The NNT in the P-NET group ranged from 3.0 to 4.2 (Solorzano et 
al., Bertani et al.). 
 
Those studies that considered additional covariates demonstrated a tendency towards 
worse outcomes in older patients, higher grade tumours, high tumour burden, and high Ki-
67 index,
14-16,19,22,23
 although these findings were not universally reported.
21
 
 
 
 
Discussion 
 
The majority of patients with EP-NET have diffuse metastatic disease at presentation. In 
these patients, curative metastatectomy is not possible, but there remains ongoing debate 
on whether removal of the primary lesion confers a survival benefit.
1,5,9,12,13,18,20,24-27
 Although 
there have been no randomised controlled trials, the present study has identified 13 papers 
which report a direct comparison between patients receiving surgery to their primary 
tumour, and those treated without surgery. In nine studies, surgery yielded a significant 
improvement in survival, with the other four studies reporting a non-significant tendency to 
improved survival (Table 2). This study presents the first meta-analysis to evaluate the role 
of primary tumour resection in terms of overall survival, for both SI-NET and P-NET. The six 
studies that reported hazard ratios all made attempts to control for confounding factors, 
and returned a pooled hazard ratio of 0.44 (95% CI: 0.35 – 0.55; p<0.001) for survival in the 
surgical, relative to the non-surgical group. Subgroup analysis demonstrated a similar benefit 
in both pancreatic and small intestinal primaries (Figure 2). 
 
The incidence of EP-NET is increasing, but the heterogeneity and varying clinical 
presentation of patients has hindered standardisation of treatment strategies and limited 
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the initiation of multicentre randomized trials, particularly in the setting of unresectable 
disease. As a result, International and National guidelines have frequently relied on Level 3 
and 4 evidence. The 2016 European Neuroendocrine Tumour Society (ENETS) consensus 
guidelines
5,12
, in addition to other recent guidelines,
9,18,26,27
 strongly support the role of 
surgery in metastatic EP-NET where complete resection of primary and metastatic disease is 
deemed feasible. Resection of the primary with synchronous or delayed liver resection can 
achieve 5 year survival rates of up to 76% in well-differentiated (Ki67<5%) P-NETs and 74% in 
well-differentiated SI-NETs.
6-11
 However, in the setting of unresectable metastatic disease, 
the value of surgery is less clear. ENETS guidelines recommend consideration of palliative 
resection of primary jejunal and ileal tumours, but do not comment specifically on the role 
of palliative primary tumour resection in P-NET.
5,12,18
 Previous ENETS guidance (2008 and 
2012) did not recommend resection of pancreatic primaries, except where there are life-
threatening intractable secretory symptoms.
17,28
 
 
These recommendations are based on early data, included in the present study, suggesting 
the potential for improved survival following resection of intestinal primaries, with the 
intention of avoiding intestinal obstruction and ischaemic complications. The contrary 
historical advice on pancreatic primaries results from concerns related to the significant 
morbidity and mortality associated with pancreatic resection, and fewer early studies 
suggesting a survival advantage. 
 
Two recent systematic reviews reported surgical outcomes following resection of pancreatic 
and intestinal primaries in incurable disease.
13,25
 Formal meta-analysis was not undertaken 
in either study, although both reported a possible increase in overall survival following 
resection. Since publication of these systematic reviews, five additional papers have 
reported multivariable hazard ratios comparing outcomes for primary resection of P-NETs 
versus no primary resection.
14,15,19,20,22
 These additional data have enabled the formal meta-
analysis presented here. 
 
Three recent retrospective population based observational studies
19,20,22
 used the 
Surveillance, Epidemiology, and End Results database to identify patients undergoing 
palliative resection of primary metastatic P-NETs.
19,20
 Franko et. al. included patients treated 
between 1973 and 2003, and Huttner et. al. included those treated from 2004 to 2011. To 
prevent duplication of data, the study by Keutgen et. al., which included data across both 
time periods, was excluded from the present analysis.
20
 Keutgen et. al. reported a median 
survival of 65 months (95% CI 60-86 months) in those who underwent primary tumour 
resection versus 10 months (95% CI 8-12 months) in those without resection (p=0.0003), and 
all three studies reported highly consistent multivariate hazard ratios demonstrating 
prolonged overall survival in the surgical group. 
 
There are no randomised controlled trials evaluating the outcomes of palliative primary EP-
NET resection in grade IV disease. The majority of included studies were retrospective 
cohort series, which may have therefore been subject to publication bias, although the 
forest plot produced from the meta-analysis gave no clear evidence that this was the case. 
Similarly, several studies made no attempt to control for confounding variables, leading to a 
likely bias towards patients who underwent resection (Table 1). In these series, resected 
patients were likely to have a smaller metastatic disease burden, lower grade tumours, and 
a better performance status. However, all those studies included in the formal meta-analysis 
did attempt to control for one or more covariates to account for this bias. 
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The present study could not control for the significant heterogeneity between tumour types, 
although several of the included studies did attempt to control for tumour biology and 
characteristics (Table 1). The meta-analysis also included both SI-NETs and P-NETs together, 
although separate sub-group analyses were performed. In addition, no attempt was made to 
subclassify the pathological types of P-NETs. This approach is consistent with 2016 ENETS 
guidelines on the management of metastatic NET, which largely does not subclassify 
recommendations based on tumour type or site of origin.
5
 
 
The present meta-analysis did not attempt to evaluate symptom response or quality of life 
implications following surgery, due to insufficient studies reporting these outcomes. In 
addition, the value of synchronous or delayed surgical debulking of liver or peritoneal 
metastases, and the role of non-surgical targeted liver therapies, were not evaluated. 
 
Surgical morbidity and mortality following SI-NET and P-NET resection were reported 
inconsistently. The large P-NET population-based studies acknowledged that these data 
were unavailable.
19,20,22
 Operative mortality where reported ranged from 0%-9% in SI-NET 
resection and 0%-3.5% in P-NET resection. There was also no data comparing outcomes in 
patients undergoing emergency surgery with those admitted via elective or semi-urgent 
pathways. 
 
In addition, there was variation in the extent of surgery performed in each series and in each 
included patient. In the majority of studies, palliative resection of the SI-NET primary tumour 
included resection of the primary plus extensive mesenteric dissection, with the aim of 
debulking or removing mesenteric lymph node metastases, whilst preserving proximal 
mesenteric vasculature. One series reported the mean length of bowel resected as 43cm, 
(range 5 - 150cm), with 12% of patients also requiring right colonic resection.
21
 Most P-NET 
series did not include operative details although, where reported, procedures reflected the 
site and extent of disease and included total pancreatectomy, pancreaticoduodenectomy, 
distal pancreatectomy, and rarely, enucleation. Keutgen et. al. demonstrated that patients 
with body or tail tumours had a longer overall survival, although this was true in both 
resected and non-resected patients, and type of surgical procedure was not included in their 
multivariate analysis.
20
 
 
The authors acknowledge that medical therapy has evolved considerably over recent years 
and that surgeons have adopted more aggressive  resection strategies with time. Therefore 
it is possible that non-operated patients treated at the beginning of study periods could 
have been disadvantaged. As a result of the wide date ranges reported by the included 
studies, and a lack of date specific outcomes in most series, meta-analysis of survival by year 
of diagnosis was not possible. A multivariate analysis of patients with P-NET treated 
between 1973 and 2011 showed that patients diagnosed after 2003 were more likely to 
undergo surgery, and had prolonged survival.
20
 However, these trends have not been 
observed after 2004.
19
 
 
The relatively indolent behaviour of EP-NET promotes a strategy of aggressive surgical 
intervention, even in the setting of metastatic disease. This is particularly true in 
symptomatic patients, with well-differentiated tumours (Ki67 <10%) and good functional 
status.
10,29,30
 The findings of the present meta-analysis, although limited by possible 
publication and selection bias, endorse a role for palliative primary tumour resection in small 
intestinal and pancreatic NETs, provided surgery can be performed with low morbidity and 
mortality. Since bias has likely favoured resection in less morbid patients with less extensive 
disease, it would seem logical that these patients in particular should be considered for 
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palliative surgery. Further work is necessary to evaluate any additional benefit of 
simultaneous hepatic and/or peritoneal debulking, cytoreductive surgery with hyperthermic 
intra-peritoneal chemotherapy and non-surgical targeted liver therapies in extensive hepatic 
involvement. Debulking surgery is currently advocated by ENETS 2016 guidelines in 
symptomatic patients where there is a stable disease burden, particularly where metastatic 
disease is localised, or where a significant proportion of the tumour burden is resectable, in 
order to decrease endocrine and local symptoms and to potentially amplify the response to 
systemic therapy.
5
 Future studies should aim to correlate survival and quality of life 
outcomes with patient and tumour-related factors including comorbidity, tumour site, Ki67 
index, and degree of tumour burden. When considering palliative surgical intervention, the 
potential survival and symptomatic benefits must be balanced against the psychological 
impact of major surgery and the risk of significant morbidity. 
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Table 1. Summary of Study Characteristics. 
 
 
        
Reference Year Total 
(primary 
resected) 
Study 
Design 
Mean 
Age 
(Years) 
Sex 
(% Male) 
Median 
Follow-up 
(Months) 
Factors adjusted for in multivariable survival analyses 
 
Pancreatic NET        
Solorzano et. al. 31 2001 96 SC RCS - - -  
Nguyen et. al. 32 2007 42 SC RCS - - 41  
Bettini et. al. 16 2009 51 SC PCS 51/57 - 26  
Franko et. al.22 2010 614 RPBOS 59/59 - - Age, Resection of Metastatic Site 
Bertani et. al.15 2014 43 SC RCS - - - Age, KI67, Liver Tumour Burden 
Du et. al.14 2015 98 SC RCS 49 53% - Age, Weight Loss, Primary NET, Primary Size, Hepatic Metastasis Size 
Huttner et. al.19 2015 442 RPBOS 53/60 51%/57% 33/18** Age, Gender, Ethnicity, Marital Status, Year of Diagnosis, Grade, T&N-stage 
Small-Intestinal NET        
Soreide et. al.21 1992 65 SC RCS 57 - -  
Givi et. al.33 2006  84+ SC RCS 57/60 50%/50% 90  
Van der Horst-Schrivers et. al. 23 2007 76# SC RCS 59 - - Age, Gamma-glutamyltransferase, Alkaline phosphatase, Urinary 5-HIAA 
Ahmed et. al.21 2009 285 Mc RCS 60/61 53% 63** Age, Ki67, Urinary HIAA, Serum Chromogranin A, Peptide Receptor Therapy, Somatostatin Analogue Therapy 
Strosberg et. al.34 2009 135 SC RCS 60* 45% -  
Norlen et. al.35 2012 579 SC RCS 63 54% 83**  
Age, sex and duration of follow up are reported as Resected/Non-resected, or for the cohort as a whole, where separate statistics were not 
quoted for the two groups. 
Studies included in the formal meta-analysis are highlighted in bold text. 
Single-centre retrospective cohort series (SC RCS); multi-centre retrospective cohort series (Mc RCS); single-centre prospective cohort series 
(SC PCS); retrospective population based observational study using a national database (RPBOS). 
*Median age; **Mean follow up. 
+Includes 8 patients that did not have SI-NET but had foregut / hindgut primaries. 
#Includes 22 patients with an unknown primary site and 7 with a colonic primary. 
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Table 2 – Survival outcomes 
  
Cox Regression  Kaplan-Meier 
Study Total N 
Adjusted HR  
(95% CI) p-Value 
5 Year Survival Median Survival 
p-Value Surgery Non-Surgery Surgery Non-Surgery 
Pancreatic NET               
Solorzano et. al.31 (2001) 96 - - 49% 16% 36 21.6 0.06 
Nguyen et. al.32 (2007) 42 - - 60% 30% - - 0.025 
Bettini et. al.16 (2009) 51 - - 40.4% 41.8% 54.3 39.5 0.74 
Franko et. al.22 (2010) 614 0.46 (0.31 - 0.68) <0.001 - - 58 12 <0.001 
Bertani et. al.15 (2014) 43 0.18 (0.05 - 0.66) 0.01 82% 58% 77 50 0.027 
Du et. al.14 (2015) 98 0.39 (0.22 - 0.70) <0.001 - - - - - 
Huttner et. al.19 (2015) 442 0.47 (0.31 - 0.70) <0.001 48% 21% - - <0.001 
Small-Intestinal NET     
Soreide et. al.21 (1992) 65 - - - - 139 69 0.03 
Givi et. al.33 (2006) 76 - - 81% 21% 159 47 <0.001 
Vd H-Schrivers et. al.23 (2007) 47 0.58 (0.31 - 1.10) 0.097 57% 44% 75 52 0.084 
Ahmed et. al.21 (2009) 285 0.26 (0.09 - 0.78)* 0.015 74% 46% 119 57 - 
Strosberg et. al.34 (2009) 135 - - - - 110 88 0.32 
Norlen et. al.35 (2012) 579 - - 75% 28% - - <0.001 
Studies reporting hazard ratios are highlighted and were included in the formal meta-analysis. 
*This was reported as a relative risk in the manuscript, but is assumed to represent a hazard ratio. 
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Figure 1. PRISMA flow diagram illustrating study selection. 
 
Figure 2 – Forest plot. The six studies reporting adjusted hazard ratios are represented. 
 
Figure 3 – Funnel Plot. Data from the six studies reporting hazard 
  
Figure 4 – Combined plot of survival outcomes. 
Ratios were produced by dividing the median survival times or five year survival rates in the 
non-surgical group by the surgical group. These were then plotted against the sample size in 
each study, with a dashed line representing the pooled hazard ratio from the meta-analysis. 
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